Powered by


                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Health Questions

   News via RSS






   Forum Archives





















   Primary Care






   Other Sections


   Research Tools

   Medical Tutorials

   Medical Software




Back to index

Cancer Chemotherapy Regimen for Head and Neck Cancer

 CBM                                                 head_neck(68)
  cisplatin....... 20 mg/sqm/day IV on days 1 to 5.
  bleomycin....... 2.5 U/sqm/day: IV day 1 and IM on days 2 to 5. 
  mitomycin....... 6 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 3 weeks.

    Israel L.  Aguilera J.  Soudant J.  Penot JC.  Breau JL.  
    Morere JF. Bleomycin and cis-platinum with or without 
    mitomycin C in 110 previously untreated patients with head and 
    neck cancer. American Journal of Clinical Oncology.  
    6(3):305-11, 1983 Jun. 
    Between November 1979 and October 1981, 110 consecutive 
    patients with previously untreated, biopsy-proven squamous 
    cell carcinoma of the head and neck, were treated by 
    chemotherapy prior to scheduled surgery and/or radiotherapy. 
    Two regimens of chemotherapy were used. The first 57 patients 
    received cis-platinum, 20 mg/m2/day for 5 consecutive days and 
    bleomycin 5 mg/m2/day as a continuous infusion over the same 5 
    days every 3 weeks (Regimen A). The next 53 patients received 
    the same schedule and dose of cis-platinum, bleomycin 2.5 
    mg/m2 every 12 hours for the same 5 consecutive days and 
    mitomycin C6 mg/m2 on day 1 of each cycle every 3 weeks 
    (Regimen B). The number of courses administered prior to 
    surgery and/or radiotherapy ranged from 1-4 depending on the 
    otorhinolaryngologist's assessment of the optimal time for 
    locoregional treatment. The overall response rate in regimen A 
    was 78% (45/57) compared to 90% for regimen B (48/53). 
    Complete responses were seen in 10/57 (18%) and 13/53 (25%) 
    patients in regimens A and B, respectively. Eight of 57 
    patients in regimen A and 6/53 in regimen B refused further 
    treatment and follow-up, and 7/53 patients in regimen B chose 
    to pursue chemotherapy (in which methotrexate replaced 
    bleomycin) rather than undergo surgery and/or radiotherapy. 
    Five of these seven patients are surviving disease-free from 
    7-12 months. In regimen A, 31/57 patients are surviving with a 
    median survival exceeding 15 months. In regimen B, 46/53 
    patients are surviving up to 14 months. Nausea and vomiting 
    induced by cis-platinum were the major side effects, seen to a 
    variable degree in all patients. No cis-platinum-induced renal 
    toxicity was observed with the 5-day regimen and none of the 
    patients had symptomatic bleomycin-induced pneumonitis. One 
    patient had a bleomycin-induced skin rash which did not 
    require discontinuation of therapy. 

advertisement.gif (61x7 -- 0 bytes)

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)




We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.